INTRODUCTION
Parainfluenza viruses 1 through 4 (PIVI through PIV4) are important human pathogens that cause upper and lower respiratory tract infections, especially in infants and small children. Together with respiratory syncytial virus, PIVs are the most frequent pathogens isolated in children with lower respiratory infections. In addition to the viruses infecting humans, PIVs include viruses that cause diseases in animals, such as Sendai virus of mice, which has been used as a model for studying the course of PIV infection. Recent work has revealed interesting aspects of the molecular biology of PIVs, and these findings can now be used in, for instance, development of new vaccine candidates.
MOLECULAR BIOLOGY

Structure
PIVs are typical members of the family Paramyxoviridae and belong to the genus Paramyxovirus (Table 1) . A number of extensive reviews have recently been published concerning their structure and replication (12, 30, 31, 60) . These RNA viruses are pleomorphic enveloped particles that are 150 to 300 nm in diameter. A structural model of the virion is shown in Fig. 1 . The virion consists of a filamentous, herringbone-like nucleocapsid core surrounded by a lipid envelope with virusspecific glycoprotein spikes. The nucleocapsid is composed of the genome, a single-stranded RNA molecule of negativesense polarity, which is tightly coated with the nucleocapsid protein (NP). The nucleocapsid structure also contains two other proteins, the phosphoprotein (P protein) and the large protein (L protein), which occur discontinuously as clusters. The NP is the most abundant protein in the virion, and it is believed to be responsible, together with the P and L proteins, for RNA-dependent RNA polymerase activity (47) .
The viral envelope contains two virus-specific glycoproteins: the hemagglutinin-neuraminidase (HN) and the fusion (F) proteins. The F protein is synthesized as a biologically inactive precursor form (Fo), which is cleaved posttranslationally with of six or seven genes that encode eight or nine proteins, some of which are not detected in the virion but participate in the virus replication cycle in the cell. The genomic RNA is never found in naked form in the cells but is always tightly bound to NP.
The organization of the parainfluenza virus genome is 3'-NP-P/CNV-M-F-(SH)-HN-L-5'. The presence or absence of the SH gene between the two glycoprotein genes divides parainfluenza viruses into two groups. The first group (including PIV3, Sendai virus, and NDV) does not contain the SH gene, whereas the second group (e.g., the animal parainfluenza virus, simian virus 5, and mumps virus, which is also a member of the family Paramyxoviridae) does. This SH gene encodes a small integral membrane protein, which is highly hydrophobic and is found only in infected cells. Its function is still unclear. Figure 2 shows a schematic representation of the PIV genome and its replication cycle. Extensive sequence analysis of PIV3, Sendai virus, and NDV genomes carried out during the past few years (10, 18, 26, 32-35, 42, 55, 64, 65, 68, 70, 81, 90, 93, [96] [97] [98] [99] 116) has shown that the 3' and 5' ends of these genomes contain the short, extracistronic noncoding regions, approximately 50 and 40 nt long, respectively. The first 20 nt at the 3' end are highly conserved among paramyxoviruses (23, 35, 92, 93, 116) The control regions are conserved (42, 54, 63, 96, 116) and are transcribed to mRNAs, whereas the short intergenic sequences are not copied.
The first gene at the 3' end of the genome is the NP gene, which is highly conserved among PIVs (32, 54, 55, 90, 92) . The length of the monocistronic NP gene of PIV3 is in the range of 1,641 to 1,850 nt, and it encodes a 515-amino-acid protein (32, 55, 90) . The P gene is a multicistronic genome region with a unique coding strategy. The P genes have continuous, discontinuous, and overlapping cistrons (36) , and, according to their coding strategy, PIVs can be divided in two groups. In the first group, PIV1 and PIV3 encode their 500-to 600-amino-acid P proteins from continuous P cistrons. The second start codon in the P gene region initiates a shorter overlapping open reading frame coding for a smaller, nonstructural C protein (33, 65, 66, 97) . The proportional quantities of the P and C proteins produced are evidently controlled at the level of translation. The dependent G residues at a precise site in the mRNA molecule; the nonstructural V protein is encoded directly by the genomic sequence (61, 76, 78, 95, 108) . A similar editing mechanism has been described for measles virus (9) , which is also a member of the Paramyxoviridae, suggesting that this phenomenon has a more general biological significance. The mechanism responsible for addition of the nontemplate residues is unknown, nor is it known whether it occurs cotranscriptionally or posttranscriptionally, but virus-encoded proteins are probably needed for this process (36, 77, 108) . The P and V proteins are amino coterminal and share 164 amino acids before the sequences diverge. The V proteins have a cysteine-rich region, which is similar to the metal-binding domains present in proteins known to bind to DNA or RNA. This cysteine-rich region has been found in all paramyxovirus P genes, suggesting that it is biologically important (78) .
The M gene is the most highly conserved gene among paramyxoviruses (34, 64, 99) , and the homology is most extensive at the carboxy-terminal third of the protein sequences. Most conserved regions represent hydrophobic regions, which may be structurally involved in membrane interactions.
The PIV3 F gene is 1,845 to 1,851 nt long and encodes a 539-amino-acid protein (18, 98) . The F gene sequences reported for a number of clinical PIV3 isolates show a very high degree of conservation at the nucleotide (>94%) and amino acid (>97%) levels (82) . The F protein contains two hydrophobic regions and a signal sequence, which is later removed through a proteolytic cleavage. Comparison of the F genes of Sendai virus and NDV indicates a close evolutionary relationship between these human and animal pathogens (5, 10, 73, 93) .
The HN genes of PIV3, Sendai virus, and simian virus 5 encode a 565-to 572-amino-acid protein containing one major hydrophobic region and no signal sequence (4, 26, 51) . The highest homology, 62% at the amino acid level, occurs between PIV3 and Sendai virus (73) .
The L gene is located at the 5' end of the genome and is the largest PIV gene (6,799 nt) . It represents about 40% of the coding capacity of the entire genome (72, 93, 116 
Proteins and Their Antigenic Structure
The PIV genomes encode six structural proteins, which are found in virions, and two (or more) nonstructural proteins, which are detected only in infected cells. Table 2 summarizes the chemical nature, location in the virion, and functions of the structural proteins.
The HN glycopolypeptide is a receptor-binding protein that mediates virus-cell attachment. It is anchored to the envelope by the hydrophobic region near its amino terminus (4, 51, 70) , whereas the F glycoprotein is anchored near its carboxy terminus. The HN protein has hemagglutinating and neuraminidase activities. Its putative three-dimensional structure is thought to be broadly similar to that of influenza virus neuraminidase, but the framework residues of the active site are less strictly conserved (17) . By using recombinant vaccinia viruses expressing the HN and F glycoproteins of PIV3, it has been shown that the HN protein is also required for complete fusion activity (25) .
The PIV3 HN protein contains six antigenic sites (A to F), most of which are conformational (15, 16, 106) . Three of these sites (A, B, and C, together containing 11 epitopes) are involved in neutralization and hemagglutination activities; in PIV3, these regions are highly conserved among clinical isolates (14, 88, 104) . However, in PIVI, HN protein genetic variation and evolution occur (49, 50) . On the other hand, the HN proteins of Sendai virus and NDV contain only four antigenic sites, but antibodies against all of them are needed for complete neutralization of the virus (52, 53, 75, 79) . In addition, glycosylation of the protein is important for antigenicity. Monoclonal antibodies to site A epitopes also inhibit neuraminidase activity, suggesting that site A is located on the PIV3 HN molecule in a region topographically close to the site of neuraminidase activity (14, 15) .
The F glycoprotein is involved in hemolysis, cell fusion, and virus penetration into the cell. It is a disulfide-linked protein composed of a distal polypeptide, F2, and a larger, proximal polypeptide, Fl, anchored to the envelope near its C-terminal end (10) . It induces neutralizing antibodies, and the PIV3 F protein contains eight antigenic sites. The existence of identical changes in F epitopes in naturally occurring PIV3 strains raises the possibility that mutations arise easily (104, 105) .
NP is the most abundant component in the nucleocapsid structure. It is tightly bound to genomic RNA, having an essential role in the stability of the nucleocapsid. NP also interacts with the P and L proteins in the nucleocapsid structure, but the precise role of NP in transcription and replication is not completely understood. It has been proposed that this polypeptide might function as a switching factor in the change from transcription to replication. The NP of PIV3 exhibits extensive homology (70%) with that of Sendai virus in the first 424 amino-terminal amino acids, but no homology is observed between the 95 carboxy-terminal amino acids (90) . Moreover, NP contains two other identical, highly conserved regions, suggesting their structural or functional importance. Like other internal components of the virions, M, P, and L proteins, NP would not be expected to induce a good humoral responses. On the other hand, these proteins may act in the induction of T-cell immunity, as has been shown with Sendai virus and measles virus NPs (22, 89) .
The P and L proteins are crucial components in RNAdependent RNA polymerase activity. P protein is the most extensively phosphorylated protein in the virion structure, although NP and L protein are also phosphorylated to some extent. L protein is the largest virus-specific protein and is believed to be responsible, together with P protein, for transcriptase activity as well as for capping, methylation, and polyadenylation of virus-specific mRNAs.
The hydrophobic M protein is found in close association with the envelope. M protein plays a critical role in the structure of the virion by mediating interaction between the nucleocapsid core and the surface glycoprotein spikes. The attachment of the nucleocapsid to glycoproteins through the M protein is thought to start the budding process of the virus particle through the plasma membrane; this is the final step in virion maturation. Tight association of M protein with the nucleocapsid structure in infected cells suggests that it may also have a regulatory role in transcription and/or replication. The fact that the M protein is highly conserved among PIV proteins also indicates that it plays an important role in virus replication (34, 99 (113) and recently also for PIV1, PIV2, and PIV3 grown in NCI-H292 cells (112) .
When more rapid demonstration of the virus is needed, detection of viral antigens by immunoassays is recommended. Radioimmunoassays and enzyme immunoassays have been developed for the detection of PIV1, PIV2, and PIV3, using either polyclonal sera (91) 64, 86 , and 21% of PIV1, PIV2, and PIV3 infections, respectively (83) . Upper respiratory tract infection was clinically diagnosed in 58% of the children with PIV3 infection. Otitis was detected in 10 to 34% of children with PIV infection while pneumonia was found in 12% of the children with PIV2 and 11% with PIV3 infections but not in those infected with PIV2. Bronchiolitis was not found in association with PIV infections in this study. The maximum temperature of these patients was approximately 40°C. Slightly elevated or normal C-reactive protein, leukocyte count, and erythrocyte sedimentation rate values were found in children with PIV infections (85 (Fig. 3 ). An (20, 56) . Serious lower respiratory tract disease caused by PIVs has been reported in children and adults who undergo bone marrow transplantation (114) . Of (69) . PIV3 has also been isolated from the blood of children with acute respiratory infection (84) .
Ciliated epithelial cells of the respiratory tract are infected (27) , and a peribronchiolar infiltrate containing lymphocytes, plasma cells, and macrophages appears, together with edema and excess secretion of mucus. When pneumonia is predominant, a moderate hyperplasia of alveolar epithelia is observed and fluid containing some macrophages, erythrocytes, and leukocytes accumulates (117) . The mechanisms of cell damage include both direct destruction by the virus and effects of the immune response (70) . The latter may consist of formation of antigen-antibody complexes, allergic injury due to IgE, cytotoxic T cells, or delayed-type hypersensitivity. The p.i. in lungs and serum, and the highest values were observed 6 h p.i.
Most reports on immunity to PIVs in humans concern local and circulating antibodies; the importance of cell-mediated immunity in clinical PIV infections is largely unknown. These viruses enter the body via the respiratory route, and so the first specific defense mechanism is the barrier of local antibodies. Smith et al. (94) studied the protective effect of antibodies in the serum and in nasal secretions in adult volunteers who were challenged intranasally with PIV1. They found that the presence of antibodies in nasal secretions is a better marker of host resistance to infection than the level of antibodies in serum. Yanagihara and McIntosh (115) have shown that in infants infected with PIV1 or PIV2, a significant increase in the level of virus-specific nasopharyngeal secretory IgA is detected. However, there was a discordance between the IgA level and neutralizing activity in individual specimens because many secretions containing IgA were not neutralizing and not all secretions with neutralizing activity contained IgA. It has been shown that in Sendai virus infection of mice, local administration of monoclonal IgA or IgG antibodies is effective in protecting the airways from viral infection (67) . On the other hand, it has been proposed that passively acquired circulating maternal antibodies might participate in the pathogenesis of PIV infections. This mechanism was not supported in experiments involving PIV3 infection in hamsters, since partial passive immunization did not enhance the severity of the disease (40) .
Reinfections with PIVs are common, as reported for infections caused by other respiratory viruses. To study the mechanism of this phenomenon and the specificity of the immune response in more detail, van and secondary infection in humans. They found that during primary infection, seronegative infants and children developed strong antibody responses with neutralizing activity whereas responses of young infants with maternal antibodies were weaker. Reinfected children exhibited antibody responses higher than those observed during primary infection. In adults, the antibody levels were lower, suggesting that they decay with time. In 90% of the children, the antibody response in primary infection was directed to four of the six antigenic sites studied in the HN glycoprotein, including three of the four neutralization sites. Response against the antigenic sites in the F glycoprotein was weaker than against HN sites and varied considerably from person to person. Reinfection broadened the site-specific responses, although the response against the F glycoprotein still remained restricted.
Rydbeck et al. (87) analyzed the protective effect of monoclonal antibodies against the glycoproteins of PIV3 in intracerebrally infected newborn hamsters. They observed that a significant degree of protection was obtained with antibodies against both HN and F glycoproteins but that none of the individual antibodies could completely protect the animals against disease.
Julkunen et al. (57) Local interferon production has been observed in 30% of PIV-infected children, whereas the corresponding percentages for respiratory syncytial and influenza virus infections were 4 and 55%, respectively (43).
PREVENTION AND TREATMENT As outlined above, PIVs are a significant cause of morbidity, especially in infants and young children, and therefore several strategies have been used for the development of effective vaccines. These have included live attenuated viruses, noninfectious viral protein components, and vaccinia virus vectors expressing PIV glycoproteins.
Live vaccines have the advantages that they induce more effective local mucosal immunity and that the duration of the protection is longer when compared with inactivated and subunit vaccines, although the inactivated and subunit vaccines may have fewer adverse effects. The first inactivated vaccines for PIV1, PIV2, and PIV3 were developed in the late 1960s (29) . However, the antibody responses were variable and no protection against disease was observed (48).
Because bovine PIV3 (bPIV3) is antigenically related to human PIV3, attempts have been made to use bPIV3 as a vaccine against human disease (the Jennerian approach). It has been shown in a cotton rat model that bPIV3 is able to induce a high level of resistance to human PIV3 (106) . Clinical evaluation of this vaccine candidate is under way (13) .
Another approach is to use selected variants of human viruses with reduced virulence. Cold-adapted, temperaturesensitive mutants of PIV3 have been used for this purpose (74) .
Cold-adapted mutants were first produced by serial passages under suboptimal conditions in cell cultures. These viruses seem to have a stable phenotype, are attenuated when evaluated in animal models, and induce resistance to wild-type PIV3 challenge in experimental animals (45) . Belshe et al. (3) evaluated passage level 18 of this cold-adapted vaccine candidate in a double-blind, randomized, placebo-controlled study in infants and young children. Of the seropositive children, none in the older age group became infected whereas some of the younger ones shed the virus. All four seronegative young children became infected with the vaccine strain, and two of them developed an illness characterized by rhinorrhea and wheezing. Furthermore, in one case, the virus spread to a sibling control (although it did not cause illness), indicating that this vaccine needs further development before it can be used safely.
In Sendai virus infection in mice, mutant viruses deficient in proteolytic processing of the F glycoprotein cause restricted infection but still are able to induce resistance to challenge by the wild-type virus (103) . Therefore one possible approach for vaccine development could be selection of corresponding mutants of the human PIV strains. It is important to keep in mind, however, that for all vaccines containing live viruses, attenuation must be stable.
It has also become possible to construct recombinant viruses (by using, e.g., vaccinia virus as a vector) which express other viral polypeptides on the surface of infected cells. In monkeys immunized intradermally with a single dose of a vaccinia virus construct expressing the HN or F glycoprotein of PIV3, replication of challenge virus was significantly restricted (100, 101) . Such new vaccines require further careful evaluation, and studies with other viruses (e.g., adenovirus) may show that they are more optimal vectors in this approach to immunization.
Subunit vaccines have also been developed for PIVs by using different strategies. Ambrose et al. (1) tested a PIV3 subunit vaccine consisting of detergent-solubilized, affinity-purified HN and F glycoproteins in cotton rats. Antibody levels observed after intramuscular immunization were similar to those observed in control animals infected intranasally with PIV3. After intranasal challenge, virus titers in the immunized animals were significantly reduced and inversely correlated with antibody levels in serum. In another study, cotton rats were immunized with the PIV3 F glycoprotein expressed in insect cells by using a baculovirus vector. Low levels of specific antibodies were detected, and the animals became moderately protected against subsequent PIV3 challenge (44). Brideau et al. (7) expressed a chimeric polypeptide containing the extracellular regions of the F and HN glycoproteins of PIV3 in insect cells by using a baculovirus vector. Immunization of cotton rats induced neutralizing antibodies, and the animals became protected against an intranasal challenge with PIV3. One risk of using inactivated virus or viral protein subunits as vaccines is the development of atypical and more severe forms of disease, as has been observed after immunization with formalin-inactivated respiratory syncytial virus preparations (59) . This adverse phenomenon can now be evaluated by using the cotton rat model, thus simplifying the development of safe vaccines (80) .
At present, the treatment of PIV infections is symptomatic. Some candidate antiviral drugs, including ribavirin, interferons, and protease inhibitors, have been tested, but more studies are needed to elucidate their efficacy.
Rapidly accumulating knowledge of PIV structure, replication, and immunopathogenesis offers a good opportunity to further develop new and more effective vaccines and antiviral drugs to prevent and treat PIV infections. Moreover, improved rapid diagnostic methods for PIVs permit specific diagnosis at an early stage of the illness and detection of single cases before the onset of an epidemic. This progress should facilitate VOL. 7, 1994 on October 19, 2017 by guest http://cmr.asm.org/ Downloaded from development of methods for prevention of respiratory infections caused by PIVs.
